Dearth of Participation From Black Patients Noted in CAR T Clinical Trials Supporting FDA Approvals

Article

Investigators identified that in pivotal clinical trials supporting FDA approvals of CAR T-cell therapies for patients with hematologic cancer, Black patients were significantly underrepresented.

Notable disparities with regard to Black patients have been observed in CAR T-cell therapy clinical trials that have led to FDA approvals in hematologic cancers, according to findings from a study published in JAMA Network Open.1

Between studies, about 2% to 5% of Black patients were enrolled in clinical trials, received CAR T therapies, and reported efficacy. Using an adjusted prevalence measure, investigators reported that the lowest participation to prevalence ratio was 0.2 for multiple myeloma and 0.6 for large B-cell lymphoma (LBCL). The lowest number of Black patients was observed in the clinical trial that led to the approval of brexucabtagene autoleucel (Tecartus) in mantle cell lymphoma, with only 1 Black patient included.

“The findings of this study suggest that low enrollment of Black persons exists in trials for CAR T therapy and that the disparity is substantial and ongoing, especially for therapies to treat [multiple myeloma]. Efforts should be made to understand and overcome barriers that lead to decreased enrollment of Black participants in clinical trials that include novel, potentially beneficial, and/or curative CAR T therapies in difficult-to-treat hematological malignant neoplasms with otherwise limited treatment options,” Samer Al Hadidi, MD, assistant professor of medicine at the University of Arkansas for Medical Sciences, said in a press release.2

Between August 2017 and March 2021, 5 CAR T products were approved across 7 indications. A total of 1057 patients were enrolled, 746 of whom received CAR T-cell therapies and 729 reported efficacy.

In the study that led to the approval of tisagenlecleucel (Kymriah) in acute lymphoblastic leukemia, patients who were Black were put in a racial category designated as other, “otherwise, their enrollment was specified mainly in the demographic subgroups information available under the FDA product labeling information.”

Investigators noted that most of the studies included in FDA approvals did not report the proportions of racial and ethnic groups. Eighteen Black patients with diffuse LBCL who were treated with CAR T-cell therapy reported efficacy per disease category. Additionally, in one CAR T-cell therapy approval study for multiple myeloma, only 6 Black patients participated, comprising 6% of the total patient population.

“The incidence of [multiple myeloma] is more than 2 times higher among Black persons than among non-Hispanic White persons,” the investigators wrote. “Black patients with [multiple myeloma] face multiple disparities, including lower use of hematopoietic stem cell transplantation, palliative care, and novel therapeutics, which may result in worse outcomes. Lack of access to novel therapies that disproportionately affect Black persons may result in further widening of the existing established disparities.”

Participation of Black Patients in Trials Supporting Approval of CAR T-Cell Therapies for Hematologic Malignancies

Participation of Black Patients in Trials Supporting Approval of CAR T-Cell Therapies for Hematologic Malignancies

On April 13, 2022, the FDA initiated a plan to increase clinical trial diversity by employing the Race and Ethnic Diversity Plan.3 This has gone into effect for companies submitting applications for investigational new drugs, biologics license application, or investigation device exemption. This new plan recommends that companies define their enrollment goals for underrepresented populations so that they may be a part of pre-specified protocol objectives.

References

  1. Al Hadidi S, Schinke C, Thanendrarajan S, Zangari M, van Rhee F. Enrollment of black participants in pivotal clinical trials supporting US Food and Drug Administration approval of chimeric antigen receptor-T cell therapy for hematological malignant neoplasms. JAMA Netw Open. 2022;5(4):e228161. doi:10.1001/jamanetworkopen.2022.8161
  2. Study: Black patients underrepresented in pivotal CAR T-cell trial. News Release. Regulatory Affairs Professionals Society. April 20, 2022. Accessed April 21, 2022. https://bit.ly/36yhrEa
  3. FDA recommends sponsors plan to include race, ethnicity in clinical trial design. News Release. Regulatory Affairs Professionals Society. April 13, 2022. Accessed April 21, 2022. https://bit.ly/3jXKILt
Recent Videos
Future meetings may address how immunotherapy, bispecific agents, and CAR T-cell therapies can further impact the AML treatment paradigm.
Treatment with revumenib appeared to demonstrate efficacy among patients with KMT2A-rearranged acute leukemia in the phase 2 AUGMENT-101 study.
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Data from the REVEAL study affirm elevated white blood cell counts and higher variant allele frequency as risk factors for progression in polycythemia vera.
Additional analyses of patient-reported outcomes and MRD status in the QuANTUM-First trial are also ongoing, says Harry P. Erba, MD, PhD.
Investigators must continue to explore the space for lisocabtagene maraleucel in mantle cell lymphoma, according to Manali Kamdar, MD.
Those with CML should discuss adverse effects such as nausea or fatigue with their providers to help optimize their quality of life during treatment.
Patients with CML can become an active part of their treatment plan by discussing any questions that come to mind with their providers.
Jorge E. Cortes, MD, emphasizes proper communication between patients with chronic myeloid leukemia and their providers during the treatment course.
Dietary interventions or other medications may help mitigate diarrhea in patients who undergo therapy for chronic myeloid leukemia.
Related Content